Related references
Note: Only part of the references are listed.Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2023)
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study
Valerio Rosato et al.
JOURNAL OF VIRAL HEPATITIS (2022)
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay et al.
LANCET (2022)
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle et al.
ADVANCES IN THERAPY (2022)
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola et al.
REVIEWS IN CARDIOVASCULAR MEDICINE (2022)
Comparative Transcriptome Analysis Reveals That Exendin-4 Improves Steatosis in HepG2 Cells by Modulating Signaling Pathways Related to Lipid Metabolism
Khaoula Errafii et al.
BIOMEDICINES (2022)
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee et al.
ENDOCRINOLOGY AND METABOLISM (2022)
Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis
Mari Kamiya et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2022)
Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes
Yijiong Tan et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2022)
Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
Qingjuan Ren et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
FRONTIERS IN ENDOCRINOLOGY (2022)
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
Yaofu Zhang et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco et al.
DIABETES CARE (2021)
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis
Santo Colosimo et al.
LIVER INTERNATIONAL (2021)
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Alfredo Caturano et al.
PROCESSES (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
FXR in liver physiology: Multiple faces to regulate liver metabolism
Katrin Panzitt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck et al.
DIABETES OBESITY & METABOLISM (2021)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik et al.
LANCET (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Teresa Salvatore et al.
FRONTIERS IN MEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Jennifer M. Trujillo et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
W. Timothy Garvey et al.
DIABETES CARE (2020)
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis
Rod S. Taylor et al.
GASTROENTEROLOGY (2020)
Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
Fu-Shun Yen et al.
LIVER INTERNATIONAL (2020)
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
Thomas A. Wadden et al.
OBESITY (2020)
Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
Aimo Kannt et al.
DIABETES OBESITY & METABOLISM (2020)
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
Mohammed Eslam et al.
JOURNAL OF HEPATOLOGY (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
Motoyasu Kojima et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
Yunyun Fang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
Hiroaki Yokomori et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial
Wen-Huan Feng et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
Niina Matikainen et al.
DIABETES OBESITY & METABOLISM (2019)
Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy
Yeonhee Hong et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2019)
Glucagon Receptor Signaling and Lipid Metabolism
Katrine D. Galsgaard et al.
FRONTIERS IN PHYSIOLOGY (2019)
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
Philip Newsome et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Fernando Bril et al.
DIABETES CARE (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Teresa Salvatore et al.
NUTRIENTS (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Jinhua Yan et al.
HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Hong Wei et al.
JOURNAL OF DIABETES RESEARCH (2019)
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al.
JHEP REPORTS (2019)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates
Ralf Elvert et al.
DIABETES OBESITY & METABOLISM (2018)
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
K. Cusi et al.
DIABETIC MEDICINE (2018)
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi et al.
ENDOCRINE REVIEWS (2018)
Regression of HCV cirrhosis: Time will tell
Guadalupe Garcia-Tsao
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis
Raffaele Marfella et al.
DIABETOLOGY & METABOLIC SYNDROME (2018)
Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice
Katsunori Nonogaki et al.
JOURNAL OF DIABETES RESEARCH (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR
Kavita Jadhav et al.
MOLECULAR METABOLISM (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents
Pia K. Norregaard et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial
Signe Frossing et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH
Eduardo Vilar-Gomez et al.
LIVER INTERNATIONAL (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
Wenhuan Feng et al.
JOURNAL OF DIABETES (2017)
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
Hani Jouihan et al.
MOLECULAR METABOLISM (2017)
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall et al.
MOLECULAR METABOLISM (2017)
Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
Ryotaro Bouchi et al.
ENDOCRINE JOURNAL (2017)
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
Houssam Halawi et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
Stefanie Amarens de Boer et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2016)
Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators
Juan Decara et al.
BIOFACTORS (2016)
GLP-1 as a target for therapeutic intervention
Surya Panicker Rajeev et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
A. Dutour et al.
DIABETES OBESITY & METABOLISM (2016)
Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide
Savvoula Savvidou et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice
Katsunori Nonogaki et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
Mark M. Smits et al.
DIABETOLOGIA (2016)
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
A. Blackman et al.
INTERNATIONAL JOURNAL OF OBESITY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
Khalidur Rahman et al.
LABORATORY INVESTIGATION (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Young-Sun Lee et al.
MEDIATORS OF INFLAMMATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo et al.
PLOS ONE (2016)
PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation
Qian Gao et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
An Tang et al.
DIABETES CARE (2015)
Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans
L. van Bloemendaal et al.
DIABETES OBESITY & METABOLISM (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
Paola Portillo-Sanchez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Islet α cells and glucagon-critical regulators of energy homeostasis
Jonathan E. Campbell et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling
Ayaka Ito et al.
ELIFE (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
Mahesh M. Umapathysivam et al.
DIABETES (2014)
Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients
Kristina Blaslov et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2014)
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
Lise L. Gluud et al.
BMJ OPEN (2014)
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
M. J. Armstrong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
Role of leptin and adiponectin in insulin resistance
Amita Yadav et al.
CLINICA CHIMICA ACTA (2013)
Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia
Tricia M. Tan et al.
DIABETES (2013)
Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala
J. A. Parker et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Yongjie Ma et al.
PHARMACEUTICAL RESEARCH (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis
Nitika A. Gupta et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
Jamie E. Mells et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
Jonathan W. Day et al.
BIOPOLYMERS (2012)
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes
G. Derosa et al.
DIABETIC MEDICINE (2012)
Activation of Liver X Receptors Attenuates Endotoxin-Induced Liver Injury in Mice with Nonalcoholic Fatty Liver Disease
Yuan Liu et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
CLINICAL USE OF LIRAGLUTIDE IN TYPE 2 DIABETES AND ITS EFFECTS ON CARDIOVASCULAR RISK FACTORS
Ajay Varanasi et al.
ENDOCRINE PRACTICE (2012)
Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Daniel J. Cuthbertson et al.
PLOS ONE (2012)
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Takamasa Ohki et al.
SCIENTIFIC WORLD JOURNAL (2012)
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Jinmi Lee et al.
DIABETES & METABOLISM JOURNAL (2012)
Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis
Jeffrey A. Handy et al.
BIOCHEMICAL JOURNAL (2011)
Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C
Elena Lima-Cabello et al.
CLINICAL SCIENCE (2011)
Up-Regulation of PPAR-γ mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induction
Paulina Pettinelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Shani Ben-Shlomo et al.
JOURNAL OF HEPATOLOGY (2011)
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis
Gianluca Svegliati-Baroni et al.
LIVER INTERNATIONAL (2011)
Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
Padma Sathyanarayana et al.
OBESITY (2011)
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
Shvetank Sharma et al.
PLOS ONE (2011)
Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
Patrick R. Kenny et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice
Kristiaan Wouters et al.
FEBS LETTERS (2010)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Adiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis
Dipali Sharma et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Alessandro Pocai et al.
DIABETES (2009)
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
J. Jendle et al.
DIABETES OBESITY & METABOLISM (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Autophagy regulates lipid metabolism
Rajat Singh et al.
NATURE (2009)
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Jonathan W. Day et al.
NATURE CHEMICAL BIOLOGY (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model
Susan L. Samson et al.
MOLECULAR THERAPY (2008)
Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis
S. Piro et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
David C. Klonoff et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
Masato Yoneda et al.
JOURNAL OF GASTROENTEROLOGY (2007)
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
John B. Buse et al.
CLINICAL THERAPEUTICS (2007)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
XK Ding et al.
HEPATOLOGY (2006)
Autophagy and aging -: The importance of maintaining clean cells
Ana Maria Cuervo et al.
AUTOPHAGY (2005)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Share Paper
